Chu, Jeffrey http://orcid.org/0009-0005-5306-3982
Shaia, Jacqueline K.
Sharma, Neha
Russell, Matthew W.
Rachitskaya, Aleksandra V.
Talcott, Katherine E.
Singh, Rishi P. http://orcid.org/0000-0001-5859-8162
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (T32 EY024236)
Foundation for the National Institutes of Health (UL1TR002548)
Research to Prevent Blindness (P30EY025585(BA-A), P30EY025585(BA-A), P30EY025585(BA-A))
Article History
Received: 7 July 2023
Revised: 14 May 2024
Accepted: 9 July 2024
First Online: 31 July 2024
Competing interests
: RPS reports personal fees from Genentech/Roche, Alcon, Novartis, Regeneron, Asclepix, Gyroscope, Bausch and Lomb, Apellis. KET reports personal fees from Genentech/Roche, research fees from Zeiss and Regenxbio. AR reports consulting fees from Alcon, Genentech, Apellis, Iveric Bio, and Zeiss, speaking fees from Apellis, Genentech, and Regeneron, and research fees from AGTC, Apellis, Genentech, and NGM Bio. AVR reports consulting fees from Alcon, Genentech, Apellis, Iveric Bio, and Zeiss, speaking fees from Apellis, Genentech, and Regeneron, and research fees from AGTC, Apellis, Genentech, and NGM Bio.